These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16751064)

  • 21. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.
    Shi W; Siemann DW
    In Vivo; 2005; 19(6):1045-50. PubMed ID: 16277020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
    Rich JN; Sathornsumetee S; Keir ST; Kieran MW; Laforme A; Kaipainen A; McLendon RE; Graner MW; Rasheed BK; Wang L; Reardon DA; Ryan AJ; Wheeler C; Dimery I; Bigner DD; Friedman HS
    Clin Cancer Res; 2005 Nov; 11(22):8145-57. PubMed ID: 16299247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.
    Sandström M; Johansson M; Andersson U; Bergh A; Bergenheim AT; Henriksson R
    Br J Cancer; 2004 Sep; 91(6):1174-80. PubMed ID: 15305185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
    Morelli MP; Cascone T; Troiani T; Tuccillo C; Bianco R; Normanno N; Romano M; Veneziani BM; Fontanini G; Eckhardt SG; De Pacido S; Tortora G; Ciardiello F
    J Cell Physiol; 2006 Aug; 208(2):344-53. PubMed ID: 16688779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific binding of modified ZD6474 (Vandetanib) monomer and its dimer with VEGF receptor-2.
    Kim YS; Li F; O'Neill BE; Li Z
    Bioconjug Chem; 2013 Nov; 24(11):1937-44. PubMed ID: 24089699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
    Siemann DW; Shi W
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1233-40. PubMed ID: 15519796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells.
    Sarkar S; Rajput S; Tripathi AK; Mandal M
    Mol Cancer; 2013 Oct; 12(1):122. PubMed ID: 24138843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
    Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
    Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition.
    Hammarsten P; Halin S; Wikstöm P; Henriksson R; Rudolfsson SH; Bergh A
    Clin Cancer Res; 2006 Dec; 12(24):7431-6. PubMed ID: 17189416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
    Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
    Yiin JJ; Hu B; Schornack PA; Sengar RS; Liu KW; Feng H; Lieberman FS; Chiou SH; Sarkaria JN; Wiener EC; Ma HI; Cheng SY
    Mol Cancer Ther; 2010 Apr; 9(4):929-41. PubMed ID: 20371720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib and radiation: a promising combination in colorectal cancer.
    Suen AW; Galoforo S; Marples B; McGonagle M; Downing L; Martinez AA; Robertson JM; Wilson GD
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):213-20. PubMed ID: 20708486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
    Langenkamp E; Zwiers PJ; Moorlag HE; Leenders WP; St Croix B; Molema G
    Anticancer Drugs; 2012 Feb; 23(2):161-72. PubMed ID: 22075979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.
    Ko J; Ross J; Awad H; Hurwitz H; Klitzman B
    J Surg Res; 2005 Dec; 129(2):251-9. PubMed ID: 16140331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.
    Morabito A; De Maio E; Di Maio M; Normanno N; Perrone F
    Oncologist; 2006; 11(7):753-64. PubMed ID: 16880234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.